Konstantinos Xynos
Chief Tech/Sci/R&D Officer at REPLIMUNE GROUP, INC.
Net worth: 617 280 $ as of 2024-05-30
Profile
Konstantinos Xynos is currently the Chief Medical Officer at Replimune Group, Inc. He previously worked as the Vice President & Head-Global Medical Affairs at Deciphera Pharmaceuticals, Inc. from 2019 to 2021.
Dr. Xynos obtained his undergraduate degree from the University of Illinois in 1991.
He later earned an MBA from the University of Strathclyde in 2013.
He also holds a doctorate degree from Aristotle University of Thessaloniki (1997) and National & Kapodistrian University of Athens (2012).
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
REPLIMUNE GROUP, INC.
0.19% | 2024-06-06 | 117,131 ( 0.19% ) | 617 280 $ | 2024-05-30 |
Konstantinos Xynos active positions
| Companies | Position | Start |
|---|---|---|
| REPLIMUNE GROUP, INC. | Chief Tech/Sci/R&D Officer | 2022-11-30 |
Former positions of Konstantinos Xynos
| Companies | Position | End |
|---|---|---|
| DECIPHERA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2020-12-31 |
Training of Konstantinos Xynos
| University of Illinois | Undergraduate Degree |
| Aristotle University of Thessaloniki | Doctorate Degree |
| National & Kapodistrian University of Athens | Doctorate Degree |
| University of Strathclyde | Masters Business Admin |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| REPLIMUNE GROUP, INC. | Health Technology |
| Private companies | 1 |
|---|---|
Deciphera Pharmaceuticals, Inc.
 Deciphera Pharmaceuticals, Inc. BiotechnologyHealth Technology Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
- Stock Market
- Insiders
- Konstantinos Xynos
